The FY2025 (Dec) proxy of Intellia Therapeutics names 20 peer companies for pay. Among Intellia Therapeutics and these peers, CEO pay was 9th highest of 11 and total shareholder return was 10th highest of 11.
9th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$4.6M$19.2M
10th highest of 11in Intellia Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$15$524
Pay peer group, FY2025 (Dec) proxy
| Madrigal Pharmaceuticals | ||
| BridgeBio Pharma | ||
| ImmunityBio | ||
| Immunovant | ||
| IDEAYA Biosciences | ||
| Vir Biotechnology | ||
| CRISPR Therapeutics AG | ||
| Beam Therapeutics | ||
| Denali Therapeutics | ||
| Relay Therapeutics | ||
| Allogene Therapeutics, Inc. | Not disclosed | Not disclosed |
| Arrowhead Pharmaceuticals | Not disclosed | Not disclosed |
| Editas Medicine, Inc. | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| Prime Medicine, Inc. | Not disclosed | Not disclosed |
| Rocket Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Sana Biotechnology, Inc. | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
| Verve Therapeutics, Inc. | Not disclosed | Not disclosed |
| Xencor | Not disclosed | Not disclosed |
20 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.